Meropenem & EDTA
Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death. It is used as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms such as Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci and Enterococcus faecali. Also for use in the treatment of bacterial meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (b-lactamase and non-b-lactamase-producing isolates), and Neisseria meningitidis.
Meropenem in unification with EDTA can exhibit more potent antimicrobial activity against ESBL producing pathogens than just Meropenem or EDTA alone
Meropenem 1000mg +EDTA 37.5mg
MODE OF ACTION:
The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding- protein (PBP) targets. Its strongest affinities are toward PBPs 2, 3 and 4 of Escherichia coli and Pseudomonas aeruginosa; and PBPs 1, 2 and 4 of Staphylococcus .
EDTA has been shown to remove Mg2+ and Ca2+ ions from the outer cell wall of Gram-negative bacteria, thereby liberating up to 50% of the LPS molecules and exposing phospholipids of the inner membrane, enhancing the efficacy of other antimicrobials.
- Nosocomial & Community acquired pneumonia
- Uncomplicated & Complicated UTI including pyelonepheritis
- Mild to Moderate bacterial septecemia
1-2 gm every 12 hour via IV injection over 3-5 minutes or infuse over 20-30 minutes
This information is for registered medical practitioner only. Anyone other than medical practitioner should consult medical practitioner before using this product.